Aligos Therapeutics (NASDAQ:ALGS) Shares Down 5.4% – What’s Next?

Aligos Therapeutics, Inc. (NASDAQ:ALGS)’s share price fell 5.4% during mid-day trading on Friday . The company traded as low as $8.10 and last traded at $8.54. 70,762 shares traded hands during mid-day trading, an increase of 106% from the average session volume of 34,363 shares. The stock had previously closed at $9.03.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Aligos Therapeutics in a research note on Wednesday.

Aligos Therapeutics Stock Down 2.3 %

The company’s fifty day simple moving average is $10.69 and its 200 day simple moving average is $13.65. The firm has a market capitalization of $688.93 million, a PE ratio of -6.61 and a beta of 2.16.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. The company had revenue of $1.06 million during the quarter. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. During the same quarter in the previous year, the business earned ($10.75) EPS. Equities research analysts forecast that Aligos Therapeutics, Inc. will post -8.2 EPS for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ALGS. Armistice Capital LLC lifted its position in shares of Aligos Therapeutics by 5.3% in the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after acquiring an additional 363,000 shares in the last quarter. Opaleye Management Inc. increased its stake in shares of Aligos Therapeutics by 25.7% during the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after buying an additional 333,000 shares during the period. Finally, Acadian Asset Management LLC raised its holdings in shares of Aligos Therapeutics by 26.1% in the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after acquiring an additional 171,490 shares in the last quarter. Hedge funds and other institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).